Eli Lilly and Company $LLY Shares Sold by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. reduced its stake in Eli Lilly by 11.0% in Q4, selling 89,342 shares and now owns 726,465 shares worth about $780.7 million, making LLY its 10th-largest holding.
• Eli Lilly posted a quarterly beat (EPS $7.54 vs. $7.48 est.; revenue $19.29B vs. $17.85B) and set FY2026 guidance at 33.50–35.00 EPS, while recent positive catalysts—Jaypirca Phase 3 results, the CrossBridge ADC acquisition, and Foundayo approval—support its growth narrative.
• Analysts have a consensus rating of Moderate Buy with an average price target of $1,224.59 (targets range roughly $880–$1,327), and institutional investors own about 82.53% of the stock.

Robeco Institutional Asset Management B.V. lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 726,465 shares of the company's stock after selling 89,342 shares during the quarter. Eli Lilly and Company comprises about 1.1% of Robeco Institutional Asset Management B.V.'s holdings, making the stock its 10th largest holding. Robeco Institutional Asset Management B.V. owned 0.08% of Eli Lilly and Company worth $780,717,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC grew its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after acquiring an additional 16 shares during the period. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the second quarter worth approximately $29,000. Steph & Co. grew its position in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company's stock worth $30,000 after acquiring an additional 29 shares during the period. Finally, 10Elms LLP grew its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after acquiring an additional 10 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Jaypirca (pirtobrutinib) posted positive Phase 3 BRUIN CLL‑322 results showing significantly extended progression‑free survival when added to venetoclax + rituximab — a fourth positive Phase 3 readout that meaningfully strengthens Lilly’s oncology franchise and potential label expansion. PR Newswire: Jaypirca Phase 3
• Positive Sentiment: Lilly acquired preclinical ADC specialist CrossBridge in a roughly $300M deal, adding antibody‑drug conjugate expertise to its oncology pipeline — an inorganic move that accelerates biologics/ADC capabilities. FierceBiotech: CrossBridge acquisition
• Positive Sentiment: Lilly expanded external AI ties by enabling Vasa Therapeutics to use Lilly’s TuneLab AI/ML drug‑discovery models — this monetizes Lilly’s platform and can accelerate external partnerships and milestone revenue. Yahoo Finance: Vasa / TuneLab
• Positive Sentiment: Regulatory approval of Foundayo (Lilly’s oral GLP‑1 weight‑loss pill) continues to underpin the company’s blockbuster growth narrative and long‑term revenue trajectory in obesity care. The Motley Fool: Foundayo approval
• Neutral Sentiment: Media speculation about a long‑term bull case (e.g., a Forbes piece arguing LLY could reach $2,000) boosts narrative optimism but is highly model‑dependent and not new fundamental news. Forbes: LLY $2,000 thesis
• Neutral Sentiment: Analyst price‑target activity is mixed — outlets show fresh raises (to $880 and to $1,327), highlighting divergent views on near‑term valuation vs. long‑term growth. Investors should note wide target dispersion. American Banking News: PT $880 American Banking News: PT $1,327
• Negative Sentiment: Competitive risk: Novo Nordisk’s new partnership with OpenAI to speed drug development underscores intensifying AI‑driven competition in the obesity/GLP‑1 space, which could pressure market share and future growth assumptions for Lilly. Pharmaceutical-Technology: Novo + OpenAI

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on LLY shares. The Goldman Sachs Group set a $1,260.00 price objective on Eli Lilly and Company in a research report on Thursday, February 5th. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $875.00 to $880.00 and gave the stock a "neutral" rating in a research report on Friday, April 10th. UBS Group reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Freedom Capital upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Finally, Morgan Stanley increased their price objective on Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,224.59.

Eli Lilly and Company Trading Down 0.7%

LLY opened at $922.83 on Wednesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The business has a fifty day simple moving average of $980.12 and a 200-day simple moving average of $980.41. The firm has a market cap of $871.91 billion, a P/E ratio of 40.21, a P/E/G ratio of 1.08 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business posted $5.32 earnings per share. The company's quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.